Bergstrom Donald A sold $162K of RLAY
Bergstrom Donald A (President, R&D) sold 8,660 shares of Relay Therapeutics, Inc. (RLAY) at $18.71 ($0.16M total) on 2026-07-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, price, and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Insider selling under 10b5-1 can be a minor sentiment input, but the filing contains no new fundamental catalyst.
What to watch
Traders may over-weight insider sales; without changes to guidance, trial results, or financing terms, the practical trading edge is small.
Background
The article is an SEC Form 4 insider transaction disclosure for Relay Therapeutics, Inc.
Ticker impact
Relay Therapeutics Form 4 shows R&D President Bergstrom sold 8,660 shares at $18.71 under a 10b5-1 plan.
Likely limited near-term impact; any effect is more about sentiment than fundamentals.
The filing is an open-market sale executed under a Rule 10b5-1 plan, with no accompanying company-specific news (earnings, trial, deal, or guidance) in the text.
Market effects
No sector read-across provided; this is company-specific insider transaction data only.
None indicated.
None indicated.
Counterpoint
Because it is a 10b5-1 plan, the sale may reflect liquidity planning rather than bearish expectations, reducing signal value.
Key entities
- issuerRelay Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderBergstrom Donald A
President, R&D, who sold shares via an open-market transaction under a 10b5-1 plan.
